Home
|Professionals
|Michelle L. Chipetine

PDF Link

Michelle L. Chipetine

Counsel

Counsel

New York
- D
  +1.212.895.4221

bWNoaXBldGluZUBjcm93ZWxsLmNvbQ==

Areas of Focus

Overview
Representative Matters
Insights
Related Practices/Industries

Overview

Michelle Chipetine is a counsel in Crowell & Moring’s New York office and a member of the firm’s Health Care and Intellectual Property groups.

Michelle’s practice focuses on patent and health care litigation and counseling health care entities and not-for-profit corporations on a wide range of regulatory, transactional, and corporate matters. Michelle works with all types of health care entities, including hospitals, pharmacies, laboratories, and health plans, seeking to comply with federal and state laws and regulations, including those related to fraud and abuse, telemedicine, licensing, and reimbursement.

Before joining Crowell & Moring, Michelle graduated cum laude from Fordham University School of Law, where she was actively involved with Fordham’s Neuroscience and Law Center. Michelle also studied neuroscience at Vassar College, where she graduated cum laude.

Career & Education

Vassar College, B.A., cum laude, neuroscience, 2015
Fordham University School of Law, J.D., cum laude, 2018
- Vassar College, B.A., cum laude, neuroscience, 2015
- Fordham University School of Law, J.D., cum laude, 2018
New York
- New York

Michelle's Insights

Blog Post | 04.29.25

Seventh Circuit Clarifies Limits on Advertising Payments under the AKS

Client Alert | 5 min read | 03.28.25
HHS Announces “Dramatic Restructuring”
Client Alert | 2 min read | 02.21.25
First Circuit Clarifies “Resulting From” Standard Under Anti-Kickback Statute, Reshaping False Claims Act Litigation
Blog Post | 01.30.25
FDA Clarifies Enforcement Policy Around Communications of Scientific Information on Unapproved Uses of Drugs and Medical Devices

View All Insights

Representative Matters

Secured a significant victory (a preliminary injunction against patent infringement through trial) on behalf of Lonza Walkersville, Inc. against Israel-based Adva Biotechnology Ltd. in a case involving point-of-care cell-therapy technology.

Michelle's Insights

Blog Post | 04.29.25

Seventh Circuit Clarifies Limits on Advertising Payments under the AKS

Client Alert | 5 min read | 03.28.25
HHS Announces “Dramatic Restructuring”
Client Alert | 2 min read | 02.21.25
First Circuit Clarifies “Resulting From” Standard Under Anti-Kickback Statute, Reshaping False Claims Act Litigation
Blog Post | 01.30.25
FDA Clarifies Enforcement Policy Around Communications of Scientific Information on Unapproved Uses of Drugs and Medical Devices

View All Insights

Insights

Blog Post | 04.29.25

Seventh Circuit Clarifies Limits on Advertising Payments under the AKS

Client Alert | 5 min read | 03.28.25

HHS Announces “Dramatic Restructuring”

Client Alert | 2 min read | 02.21.25

First Circuit Clarifies “Resulting From” Standard Under Anti-Kickback Statute, Reshaping False Claims Act Litigation

Blog Post | 01.30.25

FDA Clarifies Enforcement Policy Around Communications of Scientific Information on Unapproved Uses of Drugs and Medical Devices

Patentability Of Inventions Involving AI In Health Care Is Becoming A Key—And Complex—Issue
|
04.05.22
Law.com
3 Practice Tips For Patenting Medical Devices In A Digital Age
|
11.03.21
Law360
Addressing The Gender Gap In Patent Law
|
03.09.21
Bloomberg Law
NY Should Learn From Prop 65 Chemical-Labeling Regs
|
04.10.19
Law360
HHS Announces “Dramatic Restructuring”
|
03.28.25
First Circuit Clarifies “Resulting From” Standard Under Anti-Kickback Statute, Reshaping False Claims Act Litigation
|
02.21.25
CMS Finalizes Contested Rule on Nursing Home Staffing and Facility Assessments
|
05.16.24
OIG Issues Updated General Compliance Program Guidance: Overview of Key Elements & Changes
|
12.18.23
New York’s CON Law Amended to Require Health Equity Impact Assessment
|
01.27.23
$900 Million Increase in Medicare Part A Payments One of Many Medicare Changes for SNFs in FY 2023
|
08.10.22
Changing Hands, Not Washing Them: CMS’ First Report on Nursing Home M&A Data
|
05.10.22
Who Spilled The (Kidney) Beans? 11th Circuit Unseals Private Emails in Organ Transplant Dispute
|
12.01.21
The Facts on Fax Machines: They’re Not Dead, They’re Indefinite
|
02.16.21
HHS' OIG Tackles Involuntary Nursing Home Discharges
|
12.01.20
View All Client Alerts
“Anatomy of a Deal: Opportunities, Developments and Regulations in Health Care Transactions,” Healthcare Ounce of Prevention Seminar (HOOPS) 2023–Navigating the Rapid Developments in Health Care.
|
03.16.23
"Pending Profanity and Bankruptcy Go Together at the Supreme Court - For Trademarks," Hon. William C. Conner Inn of Court, New York, NY
|
02.28.19
Massachusetts Manufacturer Wins 'Double Pick' Patent Litigation
|
06.11.20
New Hampshire Business Review
In Massachusetts Case, Judge Declares Technology Patent-Ineligible
|
06.05.20
Mealey's IP/Tech
District Court Finds Palomar’s ‘Pick and Place’ Patent Invalid Under 101
|
06.03.20
IPWatchdog
MRSI Systems Wins Years-Long Litigation Against Palomar Technologies By Invalidating Palomar's "Double Pick" Patent
|
06.03.20
PR Newswire
Judge: Estoppel Does Not Bar Patent Defense
|
05.28.20
Massachusetts Lawyer's Weekly
Palomar Fails To Get Past Alice In Manufacturing Patent Suit
|
05.28.20
Law360
District Court Blocks Attempt to Bar New Prior Art References Based on IPR Estoppel
|
05.14.20
IPWatchdog
Palomar Technologies Inc. v. MRSI Systems LLC
|
05.12.20
Global Legal Chronicle
Palomar Loses IPR Estoppel Bid In Manufacturing Patent Fight
|
05.05.20
Law360
The Best Lawyers in America 2025 Recognizes 42 Crowell & Moring Attorneys, Three Selected as Lawyer of the Year
|
08.15.24
Crowell & Moring Elects Seven New Partners, Promotes Four to Senior Counsel, and 26 to Counsel
|
01.02.24
The Best Lawyers in America 2024 Recognizes 47 Crowell & Moring Attorneys, Two Selected as Lawyer of the Year
|
08.17.23
Crowell & Moring Advises Amazon in its $3.9 Billion Acquisition of One Medical
|
07.22.22
LITIGATION NOTE: Crowell & Moring Secures Preliminary Injunction for Lonza in Ground-Breaking Cell Therapy Patent Infringement Case
|
01.27.22
LITIGATION NOTE: Crowell & Moring Wins Summary Judgment of Invalidity: Asserted Patent Claims an Abstract Idea Known for Thousands of Years
|
06.03.20
LITIGATION NOTE: Crowell & Moring Wins First-Ever Bench Trial on IPR Estoppel
|
05.08.20
LITIGATION NOTE: Crowell & Moring Client Agilent Successfully Rebuts Preliminary Injunction Because Patent Likely Invalid
|
10.04.19
Seventh Circuit Clarifies Limits on Advertising Payments under the AKS
|
04.29.25
Crowell & Moring’s Health Law Blog
FDA Clarifies Enforcement Policy Around Communications of Scientific Information on Unapproved Uses of Drugs and Medical Devices
|
01.30.25
Crowell Health Solution’s Trends in Transformation
Stringent Requirements for Pleading Fraud Under Rule 9(b).
|
11.05.24
Crowell & Moring’s Health Law Blog
General Allegations Without Representative Examples Are Insufficient to Survive a Motion to Dismiss
|
11.01.24
Crowell & Moring’s Health Law Blog
The Anatomy of a Failed Qui Tam Case: Lessons from U.S v. Radiation Therapy Services
|
10.09.24
Crowell & Moring’s Health Law Blog
Future Promises of Compliance with Federal Laws Cannot Form the Basis of a False Claims Act Violation
|
10.01.24
Crowell & Moring’s Health Law Blog
How Much (Information) Is Too Much? Caselaw Shines a Light on Avoiding Privilege Waiver.
|
09.30.24
Crowell & Moring’s Health Law Blog
The Intricacies of Qui Tam Actions and the Role of Government Dismissals
|
09.03.24
Crowell & Moring’s Health Law Blog
Navigating the Attorney-Client Privilege Waiver Tightrope
|
07.22.24
Crowell & Moring’s Health Law Blog
Settling False Claims Act Cases Involves More than Just Cutting a Check to DOJ
|
06.17.24
Crowell & Moring’s Health Law Blog
View All Blog Posts

View All Insights

Practices

Michelle's Insights

Blog Post | 04.29.25

Seventh Circuit Clarifies Limits on Advertising Payments under the AKS

Client Alert | 5 min read | 03.28.25
HHS Announces “Dramatic Restructuring”
Client Alert | 2 min read | 02.21.25
First Circuit Clarifies “Resulting From” Standard Under Anti-Kickback Statute, Reshaping False Claims Act Litigation
Blog Post | 01.30.25
FDA Clarifies Enforcement Policy Around Communications of Scientific Information on Unapproved Uses of Drugs and Medical Devices

View All Insights

Subscribe

to the latest insights from our team